Juvenile Dermatomyositis: Advances in Basic Research, Translational Studies and Clinical care
This symposium, co-hosted by Duke University and Cure JM Foundation on March 12, 2022, provides important information on Juvenile Myositis research.
Juvenile Dermatomyositis: Advances in Basic Research, Translational Studies and Clinical care
This symposium, co-hosted by Duke University and Cure JM Foundation on March 12, 2022, provides important information on Juvenile Myositis research.
We expected to hear promising news about the potential for CAR-T therapy to treat myositis at the Global Conference on Myositis (GCOM).
What we heard was more than promising—it was astounding.
What if I told you that there was a therapy that would “reset” the immune system—virtually eliminating the autoimmune response in myositis that causes inflammation, pain, muscle weakness, and other JM conditions of which we are all too familiar.
Second-line treatments refer to options beyond steroids and methotrexate. They are designed to manage JM while reducing reliance on those medications. We understand that adding new treatments to your child’s regimen can be intimidating. However, rest assured that your doctor has carefully considered the benefits and risks of each option to design the best treatment plan for your family.
A treatment plan is based on many factors, including the severity and expression of the juvenile dermatomyositis (JDM). Each case is different and the symptoms can change over time.
Membership is free and we’ll connect you with a network of support, encouragement, and resources.
To have your fundraiser matched, add “DIY Match” in the memo of your online gift or check.